Skip to main content

Sienna Chapter 11 Bankruptcy Proceeding:

On September 17, 2019, Sienna announced that it had elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. All pleadings filed in Sienna’s Chapter 11 proceedings are maintained on the case docket for Sienna Biopharmaceuticals, Inc., Case No. 19-12051, which can be accessed through the website maintained by the United States Bankruptcy Court for the District of Delaware (http://www.deb.uscourts.gov) or an unofficial version of the case docket along with other case information is available at https://dm.epiq11.com/case/Sienna.

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
Bids due on December 2, 2019 by 5:00 p.m. Eastern Time WESTLAKE VILLAGE, Calif. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019 , the United States Bankruptcy
Toggle Summary Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November
Toggle Summary Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
WESTLAKE VILLAGE, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to  the U.S. Food and Drug Administration ( FDA ) for
Toggle Summary Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
WESTLAKE VILLAGE, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code.

SEC Filings

Events

There are currently no events to display.

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com